Art. -Nr.: HY-N0262

Cordycepin

(Synonyms: 3'-Deoxyadenosine)

13 Cited Publications

Kundenbewertung

Based on 13 publication(s) in Google Scholar

Cordycepin (3'-Deoxyadenosine) is a nucleoside derivative and inhibits IL-1β-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts (RASFs) in a dose-dependent manner. Cordycepin kills Mycobacterium tuberculosis through hijacking the bacterial adenosine kinase.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.80%
CAS. Nr.: 73-03-0
Formel: C₁₀H₁₃N₅O₃
Molecular Weight:251.24

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Cordycepin Chemical Structure

CAS. Nr.: 73-03-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (13)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Cordycepin (3'-Deoxyadenosine) is a nucleoside derivative and inhibits IL-1β-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts (RASFs) in a dose-dependent manner^[1]. Cordycepin kills Mycobacterium tuberculosis through hijacking the bacterial adenosine kinase^[2].

IC₅₀ & Target^[1]

MMP-1

MMP-3

Alle TNF Receptor Isoform-spezifische Produkte anzeigen :

Alle MMP Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
5637	IC₅₀	71.56 μM Compound: 10	Cytotoxicity against human 5637 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human 5637 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
A498	IC₅₀	85.36 μM Compound: 10	Cytotoxicity against human A498 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human A498 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
CAKI-2	IC₅₀	94.2 μM Compound: 10	Cytotoxicity against human CAKI-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human CAKI-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
COLO 205	IC₅₀	107.93 μM Compound: 10	Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
HepG2	IC₅₀	77.19 μM Compound: 10	Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
HL-60	IC₅₀	145.24 μM Compound: 10	Cytotoxicity against human HL-60 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HL-60 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
HT-29	IC₅₀	26.33 μM Compound: 10	Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
K562	IC₅₀	94.44 μM Compound: 10	Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
KG-1	IC₅₀	88.96 μM Compound: 10	Cytotoxicity against human KG-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human KG-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
L929	IC₅₀	28.7 μM Compound: 1a, Cordycepin	Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by WST-1 assay Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by WST-1 assay	[PMID: 24283924]
MCF7	IC₅₀	45.88 μM Compound: 10	Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MDA-MB-231	IC₅₀	78.63 μM Compound: 10	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MIA PaCa-2	IC₅₀	76.78 μM Compound: 10	Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MOLT-4	IC₅₀	0.1 μM Compound: 1a, Cordycepin	Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by WST-1 assay in presence of deoxycoformycin Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by WST-1 assay in presence of deoxycoformycin	[PMID: 24283924]
MOLT-4	IC₅₀	≥100 μM Compound: 1a, Cordycepin	Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by WST-1 assay Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by WST-1 assay	[PMID: 24283924]
MOLT-4	IC₅₀	85.28 μM Compound: 10	Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
MT4	ED₅₀	>50 μM Compound: 2f	Dose required to inhibit cytopathic effect of human immunodeficiency virus replication in MT-4 cells. Dose required to inhibit cytopathic effect of human immunodeficiency virus replication in MT-4 cells.	[PMID: 3172142]
PC-3	IC₅₀	85.34 μM Compound: 10	Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
RL	IC₅₀	135.06 μM Compound: 10	Cytotoxicity against human RL cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human RL cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay	[PMID: 38547648]
Vero	IC₅₀	0.5 nM Compound: Cordycepin	Anti-Herpes simplex virus type-1 activity in vero cells using plaque inhibition assay Anti-Herpes simplex virus type-1 activity in vero cells using plaque inhibition assay	[PMID: 10464017]

In Vitro

Cordycepin is a potent inhibitor of IL-1β-induced chemokine production and MMP expression and strongly blocks the p38/JNK/AP-1 signalling pathway in RASFs. The effect of Cordycepin on cellular toxicity of RASFs is assessed using MTT assay. Treatment of RASFs with Cordycepin (50 μM or 100 μM) for 24 h does not cause any significant change in cell viability. However, cell viability is slightly decreased when cells are incubated with 100 μM Cordycepin for 48 h^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 73-03-0
Appearance Solid
Molecular Weight 251.24
Formel C₁₀H₁₃N₅O₃
Color White to off-white
SMILES

OC[C@@H]1C[C@@H](O)[C@H](N2C=NC3=C2N=CN=C3N)O1
Synonyms

3'-Deoxyadenosine
Structure Classification
- Others
Initial Source
- Microorganisms
Cordyceps militaris
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (13)

All WBCell Imaging/StainingRT-PCRFlow CytometryCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nat Commun

Cordycepin prevents radiation ulcer by inhibiting cell senescence via NRF2 and AMPK in rodents. [Abstract]

2019 Jun 10;10(1):25 PMID: 31182708

Cordycepin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Jun 10;10(1):25 [Abstract]

Western blot analysis of p16 and p21 levels in irradiated control or Cordycepin (200 μM)-treated fibroblasts 7 days after radiation.

Cordycepin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Jun 10;10(1):25 [Abstract]

Treated skin fibroblasts with 200 μM Cordycepin for 3 days before irradiation and found cordycepin-treated fibroblasts exposed to radiation showed reduced levels of the DNA damage response marker γ-H2AX at early and late time points.

Cordycepin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Jun 10;10(1):25 [Abstract]

Quantification of mRNA expression for senescence secretory phenotype in irradiated control or Cordycepin (200 μM)-treated fibroblasts 7 days after radiation.

Cordycepin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Jun 10;10(1):25 [Abstract]

Fibroblasts were treated with Cordycepin (200 μM) for 72 h and harvested for detection of apoptosis using flow cytometry 24 h following exposure to radiation.

Cordycepin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Jun 10;10(1):25 [Abstract]

Cordycepin (200 μM) increased the colony forming efficiency of irradiated fibroblasts and HaCaT cells.
Adv Sci (Weinh)

Cordycepin Modulates Microglial M2 Polarization Coupled with Mitochondrial Metabolic Reprogramming by Targeting HKII and PDK2. [Abstract]

2024 Jun 18:e2304687. PMID: 38889331
Nat Plants

A molecular mechanism for embryonic resetting of winter memory and restoration of winter annual growth habit in wheat. [Abstract]

2024 Jan;10(1):37-52. PMID: 38177663
Chem Eng J

2024 Sep 20.
Free Radic Biol Med

Cordycepin ameliorates spaceflight-induced osteoporosis by preventing BMSCs oxidative stress and senescence via interacting with PI3K p110α and regulating PI3K/Akt/FOXO3 signalling. [Abstract]

2025 Feb 16:228:108-125. PMID: 39722302
Cell Mol Life Sci

Cordycepin delays postovulatory aging of oocytes through inhibition of maternal mRNAs degradation via DCP1A polyadenylation suppression. [Abstract]

2023 Nov 25;80(12):372. PMID: 38001238
Int Immunopharmacol

Cordycepin suppresses vascular inflammation, apoptosis and oxidative stress of arterial smooth muscle cell in thoracic aortic aneurysm with VEGF inhibition. [Abstract]

2023 Mar:116:109759. PMID: 36731150
Cell Signal

Cordycepin alleviates sepsis-induced cardiomyopathy by attenuating mitochondrial oxidative stress and apoptosis through modulation of the PI3K/Akt/mTOR pathway. [Abstract]

2026 Mar:139:112354. PMID: 41494591
J Biochem Mol Toxicol

NUC7738 Induces Apoptosis Through Modulating Stability of P53 in Esophageal Cancer Cells. [Abstract]

2025 Feb;39(2):e70175. PMID: 39967332
Biochem Biophys Res Commun

Cordycepin buffers anisomycin-induced fear memory deficit by restoring hippocampal BDNF. [Abstract]

2023 Jul 12:665:118-123. PMID: 37156049
Oncol Lett

Cordycepin inhibits the proliferation and progression of NPC by targeting the MAPK/ERK and β-catenin pathways. [Abstract]

2022 Jan;23(1):20. PMID: 34858524
Lett Drug Des Discov

2025 Apr.
Research Square Preprint

2022 May.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 33.33 mg/mL (132.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2 mg/mL (7.96 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9803 mL

19.9013 mL

39.8026 mL

5 mM

0.7961 mL

3.9803 mL

7.9605 mL

10 mM

0.3980 mL

1.9901 mL

3.9803 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 5.56 mg/mL (22.13 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

Protocol 2

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 12.5 mg/mL (49.75 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

RASFs (2×10⁴ cells/well) are treated with various concentrations of Cordycepin (50 μM or 100 μM). After incubation for 1 h, 12 h and 24 h, cells are washed twice with PBS, MTT (0.5 mg/mL PBS) is added to each well and incubated at 37°C for 30 min. Formazan crystals formed are dissolved by adding DMSO (100 μL/well) and the absorbance is read at 570 nm using a microplate reader^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Noh EM, et al. Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts. Rheumatology (Oxford). 2009 Jan;48(1):45-8. [Content Brief]

[2]. Huang F, et al. Cordycepin kills Mycobacterium tuberculosis through hijacking the bacterial adenosine kinase. PLoS One. 2019 Jun 14;14(6):e0218449. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.9803 mL	19.9013 mL	39.8026 mL	99.5064 mL
H₂O / DMSO	5 mM	0.7961 mL	3.9803 mL	7.9605 mL	19.9013 mL
DMSO	10 mM	0.3980 mL	1.9901 mL	3.9803 mL	9.9506 mL
	15 mM	0.2654 mL	1.3268 mL	2.6535 mL	6.6338 mL
	20 mM	0.1990 mL	0.9951 mL	1.9901 mL	4.9753 mL
	25 mM	0.1592 mL	0.7961 mL	1.5921 mL	3.9803 mL
	30 mM	0.1327 mL	0.6634 mL	1.3268 mL	3.3169 mL
	40 mM	0.0995 mL	0.4975 mL	0.9951 mL	2.4877 mL
	50 mM	0.0796 mL	0.3980 mL	0.7961 mL	1.9901 mL
	60 mM	0.0663 mL	0.3317 mL	0.6634 mL	1.6584 mL
	80 mM	0.0498 mL	0.2488 mL	0.4975 mL	1.2438 mL
	100 mM	0.0398 mL	0.1990 mL	0.3980 mL	0.9951 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Cordycepin

13 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Cordycepin

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Nucleotide Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

Medicine Food Homology Compound Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Antibiotics Library

Anti-Pancreatic Cancer Compound Library

Microbial Metabolite Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Pain-Related Compound Library

Anti-tuberculosis Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Fungal-Sourced Compound Library

Mass Spectrometry Natural Product Library

3D Diverse Fragment Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) Cordycepin

Alle TNF Receptor Isoform-spezifische Produkte anzeigen

Alle MMP Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Cordycepin Related Classifications

Art. -Nr.: HY-N0262